Valneva SE
(XBUL:AYJ)
лв
2.078
0 (0%)
Market Cap: 580.89 Mil
Enterprise Value: 669.08 Mil
PE Ratio: 0
PB Ratio: 1.33
GF Score: 46/100 Valneva SE at Jefferies Healthcare Conference Transcript
Jun 09, 2022 / 03:30PM GMT
Maurice Thomas Raycroft
Jefferies LLC, Research Division - Equity Analyst
My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies. I'd like to welcome the CEO of Valneva, Thomas Lingelbach. Thanks for joining us today, Thomas.
Thomas Lingelbach
Valneva SE - Chairman of the Management Board, President & CEO
Pleasure. Thank you.
Maurice Thomas Raycroft
Jefferies LLC, Research Division - Equity Analyst
And we're going to do a fireside chat format. So maybe to start off, for those who are new to the story, if you can provide a 1-minute intro highlighting your main products and key catalysts ahead.
Thomas Lingelbach
Valneva SE - Chairman of the Management Board, President & CEO
Yes. So Valneva is a specialty vaccine company, focusing on the commercialization and development of vaccines in areas of high unmet medical need. We have commercial products in the field of travel vaccines. And we have 3 major advanced clinical stage assets, all of them
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot